Life Science Partner places healthcare industry strategist and investment banker to guide medical device company
Life Science Partner announces the placement of Shelley Hartman as president and chief executive officer for GMP Companies, Inc. of Fort Lauderdale, Florida. In addition to her overall responsibilities for global strategy, finance, and operations, Hartman will direct GMP Companies’ continued expansion and transformation toward a greater emphasis on commercialization of its innovative products. GMP Companies’ pharmaceutical, diagnostic and medical device technologies help treat medical conditions including diabetes, glaucoma, genetic diseases, cardiovascular diseases, immunologic diseases, cancer and neurological disorders.
“Shelley will be able to put her broad talents and knowledge of the industry to great use for a company with such farreaching complexity like GMP,” says Thomas H. Callaway, Life Science Partner’s founder and president. “As a financier who has worked with some of the biggest names in the medical device and healthcare services fields, she’ll impact GMP’s strategic partnership portfolio and commercialization efforts.”
Hartman is an experienced investment banker with a background in corporate strategy and mergers and acquisitions.
Before joining GMP Companies, Hartman was vice president and managing director of Goldman Sachs’ medical technology investment banking division, a group she created to serve both emerging and established medical device companies. Also at Goldman Sachs, Hartman held the same title at the healthcare services division. In these roles, she
has helped senior executive teams define strategy at some of the nation’s largest healthcare companies.
Hartman began her career at First Boston, where she held several positions, including vice president of the mergers and acquisitions division in the firm’s healthcare division.
Hartman is a graduate of Wellesley College, with a degree in economics and math.